Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.
Colorectal Cancer
DRUG: Panitumumab+FOLFOX-4|DRUG: Panitumumab+FOLFIRI
Objective response rate, 2009-2013
% of patients whose disease becomes resectable, 2009-2013|Time to resection, 2009-2013|Duration of response, 2009-2013|Progression-free survival, 2009-2013|Time to treatment failure, 2009-2013|Time to disease relapse following surgery., 2009-2013|Adverse Events, 2009-2013|Evaluation of molecular predictive markers for response., 2009-2013
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.